Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer

In Vivo

Volumn 21, Issue 4, 2007, Pages 673-678

  Ivkovic Kapicl, Tatjana ^a   Knezevic Usaj, Slavica ^a   Djilas Ivanovic, Dragana ^a   Panjkovic, Milana ^b  

^a Institute of Oncology Sremska Kamenica   (Yugoslavia)

^b UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Breast; Carcinoma; Ductal; erbB 2; HER 2 proto oncogene protein; Imunohistochemistry; Invasive ductal carcinoma; Receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER SIZE; CONTROLLED STUDY; CORRELATIONAL STUDY; GENE OVEREXPRESSION; GENETIC CODE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PREDICTION; PROGNOSIS; PROTEIN DETERMINATION;

EID: 34547793066     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. McPherson K, Steel CM and Dixon JM: ABC of Breast disease. Breast cancer-epidemiology, risc factors, and genetics. Br Med J 321: 624-628, 2000.
2. Ross SJ and Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. The Oncologist 3: 237-252, 1998.
3. Schnitt SJ: Breast cancer in the 21st century: neu opportunities and neu challenges. Mod Pathol 14(3): 213-218, 2001.
4. Yarden Y, Baselga J and Miles D: Molecular approach to breast cancer treatment. Semin Oncol 31: 6-13, 2004.
5. Perez E A, Pusztai L and van De Vijver M: Improving patient care through molecular diagnosis. Semin Oncol 31: 14-20, 2004.
6. Piccart MJ, Mano M, Lohrisch C and Di Leo A: Herceptin for the treatment of breast cancer: what we know-and what we have yet to learn. Cancer Futures 1: 73-79, 2002.
7. Tetu B and Brisson J: Prognostic significance of Her-2/neu oncogene expression in node-positive breast cancer. The influence of the pattern of immunostaning and adjuvant therapy. Cancer 73: 2359-2365, 1994.
8. Xing W-R, Gilchrist KW and Harris CP: FISH detection of HER-2/neu oncogene ampflication in early onset breast cancer. Breast Cancer Res Treat 39: 203-212, 1996.
9. Ferrero-Pous M, Hacene K, Bouchet C, Le Doussal V, Tubiana-Hulin M and Spyratos F: Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 6: 4745-4754, 2000.
10. Ariga R, Zarif A, Korasick J, Reddy V, Siziopicou K and Gattuso P: Correlation of Her-2/neu gene ampflication with other prognostic and predictive factors in female breast carcinoma. Breast J 11(4): 278-280, 2005.
11. Prati R, Apple S K, He J, Gornbei JA and Chanh HR: Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J 11(6): 433-439, 2005.
12. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limberger E, Berteloot P, Amant F, Vergote I and Christiaens MR: Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 58: 611-616, 2005.
13. Paik S, Brayant J, Park C, Fisher B, Tan-Chin E, Hyams D, Fisher ER, Lippman ME, Wickerham DL and Wolmark N: ErbB-2 and response to doxorubicin in patients with axillary lymph-node positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361-1370, 1998.
14. Carlomagno C, Perone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR and De Placido S: C-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastasis. J Clin Oncol 14: 2702-2708, 1996.
15. Bell R, Verma S, Untch M, Cameron D and Smith I: Maximizing clinical benefit with trastuzumab. Semin Oncol 31: 35-44, 2004.
16. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG and Somerfield MR: 2000 update of recommendations for use of tumor markers in breast and colorectal cancer: clinical practice guidelines of American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878, 2001.
17. Benohr P, Henkel V, Speer R, Vogel U, Sotlar K, Aydeniz B, Reiser A, Neubauer H, Tabiti K, Wallwiener D, Clare SE and Kurek R: Her-2/neu expression in breast cancer-A comparison of different diagnostic methods. Anticancer Res 25: 1895-1990, 2005.
18. Bossard C, Bieche I, Le Doussal V, Lidereau R and Sabourin JC: Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma. Anticancer Res 25: 4679-4683, 2005.
19. Kounelis S, Kapranos N, Malamos N and Kouri-Bairaktari E: Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry. Anticancer Res 25: 939-946, 2005.
20. Sidoni A, Ferri I, Cavaliere A, Bellezza G, Scheibel M and Bucciarelli E: Detection of HER-2/neu (c-erbB-2) overexpression and amplification in breast carcinomas with ambiguous immunohistochemical results. A further contribution to defining the role of fluorescent in situ hybridization. Anticancer Res 26: 2333-2338, 2006.
21. Tavassoli F and Devilee P (eds.): World Health Organization Classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon, IARC Press, 2003.
22. Elston C, Ellis I. Assessment of histological grade. In: The Breast. Symmers W (ed.). 2nd ed. New York, Churchill Livingstone Company, pp. 365-384, 1998.
23. Ivkovic-Kapicl T, Knezevic-Usaj S, Panjkovic M and Mastilovic K: An immunohistohemical analysis of angiogenesis in invasive ductale breast carcinoma with correlations to clinicopathologic factors. Vojnosanit Pregl 6(1): 139-146, 2006 [in Serbian].
24. Birner P, Oberhuber P, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M and Jakesz R: Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7: 1669-1675, 2001.
25. Xu R, Feiner H, Li P, Yee H, Inghirami G, Delgado Y and Perle M: Differential ampflication and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesteron receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of the breast. Arch Pathol Lab Med 127: 1458-1464, 2003.
26. Schnitt SJ: Traditional and newer pathologic factors. J Natl Cancer Inst Monogr 30: 22-26, 2001.
27. Cameron D and Bell R: Optimizing treatment for patients with breast cancer. Semin Oncol 31: 4-5, 2004.
28. Almasri NM and Al Hamad M: Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res 7: 598-604, 2005.
29. Eppenberger-Castori S, Moore DH II, Thor AD, Edgerton SM, Kueng W, Eppenberger U and Benz CC: Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 34: 1318-1330, 2002.
30. Diab SG, Elledge RM and Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92: 550-556, 2000.
31. Bozcuk H, Uslu G, Pestereli E, Samur M, Ozdogan M, Karaveli S, Sargin F and Savas B: Predictor of distant metastasis at presentation in breast cancer: a study also evalueting associations among common biological indicators. Breast Cancer Res Treat 68: 239-248, 2001.
32. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Chikhlikar PR, Ghosh N, and Trivedi TI: Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Ann Surg Oncol 7(4): 305-311, 2000.
33. Hoff ER, Tubbs RR, Myles JL and Procop GW: HER-2/neu amplification in breast cancer. Stratification by tumor type and grade. Am J Clin Pathol 117(6): 916-921, 2002.
34. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfiels MD, Groner B and Hynes NE: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48: 1238-1243, 1998.
35. Donegan WL: Tumor-related prognostic factors for breast cancer. Ca Cancer J Clin 47: 28-51, 1997.
36. Ansquer Y, Mandelbrot L, Lehy T, Salomon L, Dhalnaut C, Madelenat P, Feldmann G and Walker F: Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features. Anticancer Res 25: 4535-4541, 2005.
37. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong H, Bauerfeind I, Felber M, Wang H, Beryt M, Seshadri R, Hepp H and Slamon DJ: Quantitative association between HER-2/neu and sterois hormone receptros in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95: 142-153, 2003.
38. Siziopikjou KP and Cobleigh M: The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. The Breast 16: 104-107, 2007.
39. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernardez-Boussard T, Livasy C, Cowan D, Dressier L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou Cm: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004.
40. Bankfavli A, Schmitz K, Mock T, Kemper M, Cubick C and Bocker W: Relationship between AgNOR proteins, Ki-67 antigen, p53 immunophenotype and differentiation markers in archival breast carcinomas. Anal Cell Pathol 17: 231-242, 1998.
41. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello O, Bonetti A, Nortilli R, Pelosi G and Cetto G: Ki-67 immunostaining in 322 primary breast cancers: association with clinical and pathologic variables and prognosis. Int J Cancer 74: 433-437, 1997.
42. Keshgegiann AA and Cnaan A: Proliferation markers in breast carcinoma, Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 104: 42-49, 1995.
43. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson B: Ki-67 expression in breast carcinoma. Cancer 97: 1321-1331, 2003.
44. Rudolph P, Aim P, Olsson H, Heidebrecht HJ, Ferno M, Baldetorp B and Parwaresch R: Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Hum Pathol 32(3): 311-319, 2001.
45. Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME and Sutherland DAJ: The combination of p53 mutation and neu/erbB-2 ampflication is associated with poor survival in node-negative breast cancer. J Clin Oncol 22: 86-96, 2004.
46. Sangrajrang S, Arpornwirat W, Cheirsilpa A, Thisuphakorn P, Kalalak A, Sornprom A and Soussi T: Serum p53 antibodies in correlation to other biological parameters of breast cancer. Cancer Detect Prev 27: 182-186, 2003.